Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Actos Sales Grow On Avandia's Woes, Takeda Reports

This article was originally published in PharmAsia News

Executive Summary

U.S. sales of the type 2 diabetes therapy Actos (pioglitazone) were up $117 million or 19.2 percent year over year in the first quarter of 2007, Takeda General Manager of Finance and Accounting Hiroshi Takahara reported during the company's first-quarter 2007 earnings call July 31
Advertisement

Related Content

Avandia Should Stay On Market, Committee Says
Avandia Revenues Sink Under Safety Attack
Avandia Revenues Sink Under Safety Attack
Novartis To Resubmit Galvus In Mid-2009
Advertisement
UsernamePublicRestriction

Register

SC066406

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel